ProCE Banner Activity

REACH4: Phase I/II Study of Ruxolitinib in Pediatric Patients With Untreated or Steroid-Refractory Acute Graft-vs-Host Disease

Slideset Download
Conference Coverage

Ruxolitinib plus corticosteroids demonstrated high ORR and durable responses in pediatric patients with untreated or steroid-refractory acute GVHD, with a safety profile consistent with previous experience.

Released: December 15, 2022

Expiration: December 14, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen